Navigation Links
Oramed Patent Being Granted in China for Oral Administration of Proteins
Date:5/11/2016

JERUSALEM, May 11, 2016 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that an official Notification of Granting Patent Right was issued for the Company's patent for its invention titled "Methods and Compositions for Oral Administrations of Proteins" by the State Intellectual Property Office of the People's Republic of China.

About Oramed Pharmaceuticals 

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

For more information, the content of which is not part of this press release, please visit www.oramed.com

Forward-looking statements: This press release contains forward-looking statements. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the SEC.

 

Company Contact
Oramed Pharmaceuticals
Estee Yaari
Office: +972-2-566-0001 ext. 2
US: 1-718-831-2512 ext. 2
Email: estee@oramed.com


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Oramed to Present at PIONEERS 2016, Presented by Joseph Gunnar
2. Oramed Receives Patent Term Adjustment Extending the Term of Its U.S. Patent
3. Oramed Completes Phase IIb Oral Insulin Study
4. Oramed Patent Granted in India for Oral Administration of Proteins
5. Oramed Pharmaceuticals Shareholder Letter
6. Oramed Announces Closing of Licensing and Investment Deal with HTIT for Oral Insulin Capsule in China
7. Oramed Signs up to $50 Million Licensing and Investment Agreements for Oral Insulin Capsule in China
8. Oramed Patent Allowed in the US for Oral Administration of Proteins
9. Oramed Completes Randomization of Over 50% of Patients in Phase IIb Oral Insulin Study
10. Oramed to Present at the Rodman & Renshaw Global Investment Conference
11. Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2019)... ... August 16, 2019 , ... SignatureCare Emergency Center has ... Houston, TX including Montrose, Heights, Memorial City, and Bellaire, TX. , The one-day ... Heights, is aimed at helping Houston families get their children caught up on ...
(Date:8/16/2019)... (PRWEB) , ... August 16, 2019 , ... ... Road in Gainesville GA, 30501, is a comprehensive family dental practice that serves ... within general dentistry, cosmetic dentistry , endodontics and restorative dental care. The ...
(Date:8/16/2019)... ... August 16, 2019 , ... OCT Clinical ... it has successfully completed enrollment of 690 patients for a phase III efficacy ... multicenter, randomized, double-blind, placebo-controlled, home use, parallel group clinical trial of MED2002, which ...
Breaking Medicine Technology:
(Date:8/21/2019)... ... August 21, 2019 , ... Alsana ... in Huntsville, Ala. in early 2020. Alsana will offer an eating disorder treatment ... Outpatient Program (IOP). The integrative program will provide a continuum of care as ...
(Date:8/21/2019)... ... August 21, 2019 , ... Future ... July 28. The Phase II expansion of Providence Point in Pittsburgh’s Scott Township ... as construction of the 70-unit apartment tower, Hamilton Tower. , The ...
(Date:8/19/2019)... ... 2019 , ... Professional Enrollment Concepts (PEC), a top benefits ... have ranked #3056 on the 2019 Inc. 5000 Fastest-Growing Private Companies list. The ... most successful companies within the American economy's most dynamic segment—its independent small and ...
(Date:8/17/2019)... ... August 17, 2019 , ... ... America’s Fastest-Growing Private Companies—the Inc. 5000 , For the 2nd Year In a ... Revenue Growth of 192% Percent , Inc. magazine today revealed that YellowTelescope LLC ...
(Date:8/16/2019)... ... August 16, 2019 , ... Tim Stouffer, ICS ... Mid-Atlantic and North East at the 2019 Safety Academy sponsored through Associated Builders ... existing construction safety concepts and define not only a safety program but focus ...
Breaking Medicine News(10 mins):